12:00 AM
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

IMO-2055: Phase II data

Top-line data from an open-label, international Phase II trial in 106 patients with recurrent or metastatic SCCHN who were naïve to Erbitux cetuximab showed that once-weekly subcutaneous 0.32 mg/kg IMO-2055 plus Erbitux missed the primary endpoint of median PFS vs. Erbitux alone. Specifically, median PFS as determined by the investigator's assessment was 2.9 months in both arms, while median PFS as determined by an independent radiology review was 1.5 months for IMO-2055 plus Erbitux vs. 1.9 months for Erbitux alone. Last year, Idera regained rights to...

Read the full 417 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >